- Home
- NVAX vs EOS Comparison
NVAX vs EOS Comparison
Compare NVAX & EOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVAX
- EOS
- Stock Information
- Founded
- NVAX 1987
- EOS 2005
- Country
- NVAX United States
- EOS United States
- Employees
- NVAX N/A
- EOS N/A
- Industry
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- EOS Trusts Except Educational Religious and Charitable
- Sector
- NVAX Health Care
- EOS Finance
- Exchange
- NVAX Nasdaq
- EOS Nasdaq
- Market Cap
- NVAX 1.4B
- EOS 1.3B
- IPO Year
- NVAX 1995
- EOS N/A
- Fundamental
- Price
- NVAX $8.38
- EOS $24.29
- Analyst Decision
- NVAX Buy
- EOS
- Analyst Count
- NVAX 6
- EOS 0
- Target Price
- NVAX $17.83
- EOS N/A
- AVG Volume (30 Days)
- NVAX 4.8M
- EOS 84.1K
- Earning Date
- NVAX 02-26-2025
- EOS 01-01-0001
- Dividend Yield
- NVAX N/A
- EOS 6.80%
- EPS Growth
- NVAX N/A
- EOS N/A
- EPS
- NVAX N/A
- EOS N/A
- Revenue
- NVAX $885,193,000.00
- EOS N/A
- Revenue This Year
- NVAX N/A
- EOS N/A
- Revenue Next Year
- NVAX N/A
- EOS N/A
- P/E Ratio
- NVAX N/A
- EOS N/A
- Revenue Growth
- NVAX N/A
- EOS N/A
- 52 Week Low
- NVAX $3.60
- EOS $15.62
- 52 Week High
- NVAX $23.86
- EOS $20.63
- Technical
- Relative Strength Index (RSI)
- NVAX 45.04
- EOS 54.69
- Support Level
- NVAX $8.30
- EOS $23.61
- Resistance Level
- NVAX $9.77
- EOS $24.54
- Average True Range (ATR)
- NVAX 0.56
- EOS 0.41
- MACD
- NVAX -0.06
- EOS 0.01
- Stochastic Oscillator
- NVAX 12.67
- EOS 65.08
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.
About EOS Eaton Vance Enhance Equity Income Fund II
Eaton Vance Enhanced Equity Income Fund II is a diversified, closed-end management investment company. The fund's primary investment objective is to provide current income, with a secondary objective of capital appreciation. It invests in a portfolio of large and mid-cap securities in the sectors such as Information Technology, Consumer Discretionary, Communication Services, Healthcare, Industrials, Consumer Staples, Financials, Materials, and Energy.